kwic
observed
observed
right
off
ON
370
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for observed out of >500 occurrences
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to observed]
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [cache]
| 370) Umbilical cord blood (UCB) transplantation has observed a significant increase in recent years, due to the unique features of UCB haematopoietic stem/progenitor cells (HSCs) for the treatment of blood-related disorders. |
| PMID:23564692 DOI:10.1002/term.1741 |
| 2015 Journal of tissue engineering and regenerative medicine |
| * Stem cell bioengineering strategies to widen the therapeutic applications of haematopoietic stem/progenitor cells from umbilical cord blood. |
| - Umbilical cord blood (UCB) transplantation has observed a significant increase in recent years, due to the unique features of UCB haematopoietic stem/progenitor cells (HSCs) for the treatment of blood-related disorders. However, the low cell numbers available per UCB unit significantly impairs the widespread use of this source for transplantation of adult patients, resulting in graft failure, delayed engraftment and delayed immune reconstitution. In order to overcome this issue, distinct approaches are now being considered in clinical trials, such as double-UCB transplantation, intrabone injection or ex vivo expansion. In this article the authors review the current state of the art, future trends and challenges on the ex vivo expansion of UCB HSCs, focusing on culture parameters affecting the yield and quality of the expanded HSC grafts: novel HSC selection schemes prior to cell culture, cytokine/growth factor cocktails, the impact of biochemical factors (e.g. O2 ) or the addition of supportive cells, e.g. mesenchymal stem/stromal cell (MSC)-based feeder layers) were addressed. Importantly, a critical challenge in cellular therapy is still the scalability, reproducibility and control of the expansion process, in order to meet the clinical requirements for therapeutic applications. Efficient design of bioreactor systems and operation modes are now the focus of many bioengineers, integrating the increasing 'know-how' on HSC biology and physiology, while complying with the GMP standards for the production of cellular products, i.e. through the use of commercially available, highly controlled, disposable technologies. |
[
right
kwic]
(1)155  in |
(9)9 on |
(17)4 a |
(25)2 data |
| (2)48 *null* | (10)8 by |
(18)4 during |
(26)2 experimentally |
| (3)36 that |
(11)8 to |
(19)4 the |
(27)2 reduction |
| (4)19 for |
(12)8 when |
(20)3 variation |
(28)2 significant |
| (5)18 at |
(13)6 among |
(21)2 as |
(29)2 through |
| (6)16 between |
(14)6 following |
(22)2 changes |
(30)2 throughout |
| (7)11 with |
(15)5 after |
(23)2 clinical |
(31)2 up |
| (8)9 and |
(16)5 from |
(24)2 compared |
(32)2 using |
add keyword
--- WordNet output for observed ---